0000000000255529

AUTHOR

Axel Rominger

0000-0002-1954-736x

showing 5 related works from this author

SPECT-Untersuchungen mit dem 123I-markierten Dopamintransporter-Liganden FP-CIT (DaTSCANTM)

2019

ZusammenfassungDie S1-Leitlinie soll bei der Indikationsstellung, Durchführung, Interpretation und Befundung von SPECT-Untersuchungen des Dopamintransporters (DAT) mit DaTSCANTM unterstützen. Gegenüber der Vorgängerversion von 2007 berücksichtigt die vorliegende Aktualisierung und Überarbeitung die neuere wissenschaftliche Literatur, zwischenzeitlich veröffentlichte Guidelines der europäischen (EANM) und amerikanischen Fachgesellschaften (SNM), sowie die aktuelle Fassung der S3-Leitlinie „Idiopathisches Parkinson-Syndrom“ der Deutschen Gesellschaft für Neurologie. Zudem finden neue technische Möglichkeiten Berücksichtigung.

medicine.medical_specialtybiologybusiness.industrymedicinebiology.proteinRadiology Nuclear Medicine and imagingMedical physicsGeneral MedicineGuidelinebusinessDopamine transporterNuklearmedizin
researchProduct

AAZTA5-BN as a Versatile Probe for Radiometal Labelling, Nuclear Imaging and Radionuclide Therapy of Gastrin Releasing Peptide Positive Tumors

2021

Nuclear imagingChemistryGastrin-releasing peptideLabellingRadionuclide therapyCancer research59. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin
researchProduct

Relationship Between Body Mass Index, ApoE4 Status, and PET-Based Amyloid and Neurodegeneration Markers in Amyloid-Positive Subjects with Normal Cogn…

2018

Body weight loss in late-life is known to occur at a very early stage of Alzheimer's disease (AD). Apolipoprotein E4 (ApoE4) represents a major genetic risk factor for AD and is linked to an increased cortical amyloid-β (Aβ) accumulation. Since the relationship between body weight, ApoE4, and AD pathology is poorly investigated, we aimed to evaluate whether ApoE4 allelic status modifies the association of body mass index (BMI) with markers of AD pathology. A total of 368 Aβ-positive cognitively healthy or mild cognitive impaired subjects had undergone [18F]-AV45-PET, [18F]-FDG-PET, and T1w-MRI examinations. Composite cortical [18F]-AV45 uptake and [18F]-FDG uptake in posterior cingulate cor…

0301 basic medicineMaleApolipoprotein E4Body Mass Index0302 clinical medicineCognitionWeight lossCognitive declineAniline CompoundsGeneral NeuroscienceNeurodegenerationBrainCognitionNeurodegenerative DiseasesGeneral MedicinePsychiatry and Mental healthClinical PsychologyEthylene GlycolsFemalemedicine.symptommedicine.medical_specialtyAmyloidHeterozygote03 medical and health sciencesFluorodeoxyglucose F18Internal medicinemental disordersWeight LossmedicineHumansCognitive DysfunctionEffects of sleep deprivation on cognitive performanceAdaptor Proteins Signal TransducingAgedbusiness.industryZebrafish Proteinsmedicine.diseaseCortex (botany)Repressor Proteins030104 developmental biologyEndocrinologyGlucosePosterior cingulatePositron-Emission TomographyGeriatrics and GerontologyRadiopharmaceuticalsbusinessNeuroscienceBody mass index030217 neurology & neurosurgeryFollow-Up StudiesJournal of Alzheimer's disease : JAD
researchProduct

FDG-PET mapping the brain substrates of visuo-constructive processing in Alzheimer´s disease

2010

The anatomical basis of visuo-constructive impairment in AD is widely unexplored. FDG-PET can be used to determine functional neuronal networks underlying specific cognitive performance in the human brain. In the present study, we determined the pattern of cortical metabolism that was associated with visuo-constructive performance in AD. We employed two widely used visuo-constructive tests that differ in their demand on visual perception and processing capacity. Resting state FDG-PET scans were obtained in 29 probable AD patients, and cognitive tests were administered. We made a voxel-based regression analysis of FDG uptake to scores in visual test performance, using the SPM5 software. Perf…

MaleVisual perceptiongenetic structuresPrecuneusNeuropsychological TestsBrain mappingVisual processingFolic AcidAlzheimer DiseaseFluorodeoxyglucose F18medicineHumansBiological PsychiatryAgedAged 80 and overBrain MappingVisual testCognitive neuroscience of visual object recognitionBrainLimbic lobeHuman brainMiddle AgedVitamin B 12Psychiatry and Mental healthmedicine.anatomical_structurenervous systemPositron-Emission TomographyLinear ModelsVisual PerceptionFemaleMental Status SchedulePsychologyNeurosciencePhotic StimulationJournal of Psychiatric Research
researchProduct

New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress.

2021

Over the past decade, the tumor microenvironment (TME) has become a new paradigm of cancer diagnosis and therapy due to its unique biological features, mainly the interconnection between cancer and stromal cells. Within the TME, cancer-associated fibroblasts (CAFs) demonstrate as one of the most critical stromal cells that regulate tumor cell growth, progression, immunosuppression, and metastasis. CAFs are identified by various biomarkers that are expressed on their surfaces, such as fibroblast activation protein (FAP), which could be utilized as a useful target for diagnostic imaging and treatment. One of the advantages of targeting FAP-expressing CAFs is the absence of FAP expression in q…

fibroblast activation proteincongenital hereditary and neonatal diseases and abnormalitiesStromal cellmedicine.medical_treatmentcancer-associated fibroblastPharmaceutical Science610 Medicine & healthCancer imagingReviewfibroblast activation protein inhibitorMetastasisPharmacy and materia medicaFibroblast activation protein alphaDrug Discoverymedicinetumor microenvironment610 Medicine & healthneoplasmsradiotherapynuclear imagingTumor microenvironmentbusiness.industryRCancerImmunosuppressionmedicine.diseasedigestive system diseasesRadiation therapyRS1-441Cancer researchMolecular MedicineMedicinebusiness
researchProduct